查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614059

Duchenne氏肌肉失養症治療藥物市場：按藥物類型、給藥方法和最終用途分類 - 全球預測 2025-2030

Duchenne Muscular Dystrophy Drugs Market by Drug Type (Casimersen, Deflazacort, Delandistrogene Moxeparvovec), Administration Method (Oral, Parental), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Duchenne氏肌肉失養症治療藥物市場2023年估值為15.7億美元，預計2024年將達17億美元，複合年成長率為8.61%，預計到2030年將達到28億美元。

Duchenne氏肌肉失養症(DMD) 治療市場重點關注旨在治療 DMD 症狀和減緩 DMD 進展的藥物，DMD 是一種罕見的遺傳性疾病，其特徵是進行性性肌肉退化和肌肉無力。由於沒有明確的治療方法，因此對此類治療劑的需求是顯而易見的，因此改善生活品質和延長壽命的治療至關重要。這些藥物主要用於控制疾病症狀和維持肌肉力量，並且由於發病較早而適合兒科使用。主要最終用戶包括醫院、專科診所和研究機構。市場開拓的主要驅動力是意識的提高、基因研究的進步以及鼓勵孤兒藥開發的監管激勵措施。目前，基因療法、外顯子跳躍藥物、皮質類固醇等具有巨大的市場潛力。存在機會瞄準開拓的市場並透過基因分析技術增強個人化醫療方法。然而，市場開拓受到高昂的藥物開發成本、監管挑戰以及 DMD 遺傳學的複雜性的限制，這影響了治療的標準化。此外，患者數量有限限制了其廣泛的商業性用途。創新領域包括CRISPR等新基因編輯技術、下一代外顯子跳躍藥物的開發以及利用人工智慧加速藥物發現過程。市場仍然充滿活力，製藥公司擴大建立策略夥伴關係，以加強其研究和商業化能力。然而，跟上監管更新並解決圍繞基因治療的倫理問題仍然是一個緊迫的挑戰。情勢不斷發展，培育了一個強大的研發生態系統，這對於促進突破至關重要。為了利用現有機會，鼓勵公司優先考慮與研究界的合作，建立跨行業夥伴關係，並倡導靈活的法律規範以加快醫藥品認證過程。此類措施可提升競爭優勢，同時確保 DMD 治療領域的市場持續擴張。

主要市場統計
基準年[2023] 15.7億美元
預計年份 [2024] 17億美元
預測年份 [2030] 28億美元
複合年成長率（%） 8.61%

市場動態：快速發展的Duchenne氏肌肉失養症治療市場的關鍵市場洞察

Duchenne氏肌肉失養症營養不良症藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 包括Duchenne氏肌肉失養症在內的遺傳性疾病盛行率增加
    • 遺傳學研究不斷取得進展，闡明DMD遺傳基礎取得突破
  • 市場限制因素
    • DMD藥物成本高
  • 市場機會
    • CRISPR/Cas9等基因編輯工具與基因編輯技術的進步
    • 開發適合個人遺傳特徵的個人化醫療方法
  • 市場挑戰
    • DMD 治療藥物認知度低且副作用大

波特的五力：駕馭Duchenne氏肌肉失養症營養不良症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Duchenne氏肌肉失養症治療藥物市場的外部影響

外部宏觀環境因素在塑造Duchenne氏肌肉失養症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解Duchenne氏肌肉失養症治療藥物市場的競爭狀況

對Duchenne氏肌肉失養症治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣Duchenne氏肌肉失養症治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估Duchenne氏肌肉失養症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為Duchenne氏肌肉失養症治療藥物市場的成功指明道路

對Duchenne氏肌肉失養症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 包括Duchenne氏肌肉失養症在內的遺傳性疾病盛行率增加
      • 遺傳學研究的持續進展以及 DMD 遺傳基礎的突破
    • 抑制因素
      • DMD藥物治療高成本
    • 機會
      • CRISPR/Cas9等基因編輯工具與技術的進步
      • 開發適合個人遺傳特徵的個人化醫療方法
    • 任務
      • DMD 藥物認知度低和副作用
  • 市場區隔分析
    • 藥物類型：Casimersen 作為Duchenne氏肌肉失養症的標靶治療越來越受歡迎
    • 最終用途：門診中心更多採用 DMD 藥物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Duchenne氏肌肉失養症治療藥物市場（依藥物類型）

  • 克什默森
  • 德弗拉札外套
  • 德萊恩肌肉營養不良劑莫克斯帕沃韋克
  • 埃特普里森
  • 戈羅迪爾森
  • 維爾特拉爾森

第7章Duchenne氏肌肉失養症治療藥物市場（依管理方式）

  • 口服
  • 監護人

第8章Duchenne氏肌肉失養症治療藥物市場：依最終用途分類

  • 門診中心
  • 家庭護理設置
  • 醫院/診所

第9章北美和南美Duchenne氏肌肉失養症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區Duchenne氏肌肉失養症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲Duchenne氏肌肉失養症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Agamly 獲得 FDA核准作為第一個用於治療Duchenne氏肌肉失養症的“解離類固醇發炎藥”
    • FDA核准新的類固醇發炎藥物治療Duchenne氏肌肉失養症
    • FDA核准首個基因療法治療選定的Duchenne氏肌肉失養症症患者
  • 戰略分析和建議

公司名單

  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wallace Pharmaceuticals Pvt Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.
Product Code: MRR-5E3B35529469

The Duchenne Muscular Dystrophy Drugs Market was valued at USD 1.57 billion in 2023, expected to reach USD 1.70 billion in 2024, and is projected to grow at a CAGR of 8.61%, to USD 2.80 billion by 2030.

The Duchenne Muscular Dystrophy (DMD) Drugs market focuses on pharmaceuticals designed to treat symptoms or slow the progression of DMD, a rare genetic disorder characterized by progressive muscle degeneration and weakness. The need for such drugs is underscored by the absence of a definitive cure, thus making treatment for quality of life improvement and life extension vital. Applications of these drugs predominantly involve disease symptom management and muscle strength preservation, tailored to pediatric use due to the early onset of the disorder. Key end-users include hospitals, specialty clinics, and research institutions. Market growth is primarily driven by increasing awareness, advancements in genetic research, and regulatory incentives fostering orphan drug development. Gene therapy, exon-skipping drugs, and corticosteroids currently hold significant market potential. An opportunity exists in targeting untapped markets and enhancing personalized medicine approaches through genetic profiling technologies. However, the market encounters limitations such as high drug development costs, regulatory challenges, and the intricate nature of DMD genetics impacting treatment standardization. Additionally, a limited patient population imposes constraints on widespread commercial viability. Innovation areas include novel gene-editing techniques like CRISPR, development of next-generation exon-skipping drugs, and leveraging AI for accelerated drug discovery processes. The market remains dynamic, with pharmaceutical firms increasingly engaging in strategic partnerships to enhance research and commercialization capabilities. Nevertheless, adapting to regulatory updates and addressing the ethical concerns around genetic treatments remain pressing challenges. The landscape continues to evolve, promoting robust research and development ecosystems crucial for fostering breakthroughs. To leverage existing opportunities, firms are encouraged to prioritize collaborations with research communities, engage in cross-industry partnerships, and advocate for flexible regulatory frameworks to expedite the drug approval processes. Such measures can facilitate a competitive edge while ensuring sustainable market expansion in the DMD drug domain.

KEY MARKET STATISTICS
Base Year [2023] USD 1.57 billion
Estimated Year [2024] USD 1.70 billion
Forecast Year [2030] USD 2.80 billion
CAGR (%) 8.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Duchenne Muscular Dystrophy Drugs Market

The Duchenne Muscular Dystrophy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
    • Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
  • Market Restraints
    • High costs of DMD drug therapies
  • Market Opportunities
    • Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
    • Development of personalized medicine approaches tailored to individual genetic profiles
  • Market Challenges
    • Limited awareness and side affects associated with DMD drugs

Porter's Five Forces: A Strategic Tool for Navigating the Duchenne Muscular Dystrophy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Duchenne Muscular Dystrophy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Duchenne Muscular Dystrophy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Duchenne Muscular Dystrophy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Duchenne Muscular Dystrophy Drugs Market

A detailed market share analysis in the Duchenne Muscular Dystrophy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Duchenne Muscular Dystrophy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Duchenne Muscular Dystrophy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Duchenne Muscular Dystrophy Drugs Market

A strategic analysis of the Duchenne Muscular Dystrophy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Casimersen, Deflazacort, Delandistrogene Moxeparvovec, Eteplirsen, Golodirsen, and Viltolarsen.
  • Based on Administration Method, market is studied across Oral and Parental.
  • Based on End-Use, market is studied across Ambulatory Centres, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
      • 5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of DMD drug therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
      • 5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and side affects associated with DMD drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
    • 5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Casimersen
  • 6.3. Deflazacort
  • 6.4. Delandistrogene Moxeparvovec
  • 6.5. Eteplirsen
  • 6.6. Golodirsen
  • 6.7. Viltolarsen

7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Duchenne Muscular Dystrophy Drugs Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Centres
  • 8.3. Homecare Settings
  • 8.4. Hospitals & Clinics

9. Americas Duchenne Muscular Dystrophy Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Agamree Receives FDA Approval as First "Dissociative Steroidal Anti-Inflammatory" to Treat Duchenne Muscular Dystrophy
    • 12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
    • 12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anuh Pharma Limited
  • 2. Arlak Biotech Pvt.Ltd.
  • 3. Aurigene Pharmaceutical Services Ltd.
  • 4. Bayer Pharmaceutical
  • 5. Cipla Inc.
  • 6. Enomark
  • 7. Glasier Wellness, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Johnson & Johnson Services, Inc.
  • 10. Leo Pharma
  • 11. Lifecare Neuro Products Limited
  • 12. Mankind Pharma Ltd.
  • 13. Merck & Co., Inc.,
  • 14. MODASA Pharmaceuticals Pvt. Ltd.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. QndQ Derma
  • 18. RayBiotech, Inc.
  • 19. Ronyd Healthcare Pvt Ltd.
  • 20. Sarepta Therapeutics, Inc.
  • 21. Sumitomo Corporation
  • 22. Texas Pharmaceuticals Pvt. Ltd.
  • 23. Wallace Pharmaceuticals Pvt Ltd.
  • 24. Wellona Pharma
  • 25. Zuventus Healthcare Ltd.

LIST OF FIGURES

  • FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023